Loading Events

Annexon Virtual R&D Day: Guillain-Barré Syndrome – A Focus on the Serious Unmet Need and Annexon’s Novel Therapeutic Approach

Banners (15)
DATE: March 1, 2024
TIME: 10:00 AM EST

About The Event

Join Annexon Biosciences for an overview of Guillain-Barré Syndrome (GBS), the most common cause of acute neuromuscular paralysis, featuring GBS experts:

  • Lisa Butler, Executive Director, GBS|CIDP Foundation International
  • Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology, University of Glasgow
  • David Cornblath, MD, Professor Emeritus of Neurology, Johns Hopkins University School of Medicine

Key highlights:

  • Current treatment landscape and opportunities for new therapies from the patient and clinician perspective
  • Targeting C1q in GBS with ANX005, Annexon’s investigational monoclonal antibody designed to inhibit C1q and stop classical complement pathway activation before it starts
  • Annexon’s pivotal Phase 3 trial expected to read out in the second quarter of this year
  • The GBS market opportunity and Annexon’s commercial approach

A live question and answer will follow the formal presentation.